Diagnostics

Our focus is to implement innovative diagnostic solutions to enable precision medicine, including, but not limited to, companion and complementary diagnostic testing.

Companion diagnostics are essential for regulatory approval and use of certain precision medicines. These tests are generally co-developed and submitted for regulatory approvals in tandem with drug candidates and included in drug labels, subject to regulatory approval.

Complementary diagnostics are useful in identifying a population that may respond particularly well to a potential treatment, in identifying an underdiagnosed condition as well as diagnosis of various disease states. These tests are not considered essential to prescribing an approved drug and are not included in drug labels.

Pfizer has a diverse pharmaceutical portfolio, and we are interested in a wide range of diagnostic technologies, including companion diagnostics and complementary diagnostics. Relevant diagnostics technologies include, but are not limited to, the following:

• Near-patient Point-of-Care technologies
• Next Generation Sequencing technologies that can use multiple specimen types, including tissue and blood
• Circulating tumor cells
• Circulating cell-free nucleic acids, including potential early cancer detection
• Antigen receptor sequencing
• Neutralizing antibody assays
• Covid and other infectious disease testing platforms

The above would ideally be paired with capabilities and footprint for distribution in global markets, regulatory and reimbursement strategies, and commercialization capabilities.